

Reference number
2790-H

SPECIALTY QUANTITY LIMIT PROGRAM

Lorbrena (lorlatinib)

I. PROGRAM DESCRIPTION

The initial limit is designed to allow a quantity sufficient for the most common uses of the medication. The recommended dosing parameters for all FDA-approved indications fall within the standard limits. Coverage of an additional quantity may be reviewed on a case-by-case basis upon request.

II. COVERED QUANTITIES

Medication	Standard Limit	FDA-recommended dosing
Lorbrena 100 mg tablets	30 per 30 days	Standard dosing: 100 mg per day
Lorbrena 25 mg tablets	90 per 30 days	Recommended dose reductions for adverse reactions: <ul style="list-style-type: none"> - First dose reduction: 75 mg per day - Second dose reduction: 50 mg per day

III. REFERENCE

1. Lorbrena [package insert]. New York, NY: Pfizer, Inc.; November 2018.